Hutchmed says FDA grants orphan drug designation to sovleplenib for autoimmune hemolytic anemia
HCM•Hutchmed said the FDA granted orphan drug designation to sovleplenib for autoimmune hemolytic anemia.
1. FDA designation
Hutchmed said the FDA granted orphan drug designation to sovleplenib for autoimmune hemolytic anemia.
